TRK-950 + gemcitabine + carboplatin

This is a combination therapy comprising **TRK-950** (a humanized monoclonal IgG1 antibody targeting CAPRIN-1), **gemcitabine** (a nucleoside analog antineoplastic agent), and **carboplatin** (a platinum-based chemotherapy drug). - **TRK-950**: Binds to human CAPRIN-1 (Cytoplasmic Activation/Proliferation-Associated Protein-1), overexpressed in many solid tumors. TRK-950 promotes tumor cell death primarily via antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated phagocytosis (ADCP). This agent increases tumor-infiltrating immune cells, predominantly macrophages, and is being developed for solid tumors[1]. - **Gemcitabine**: Inhibits DNA synthesis in proliferating tumor cells, leading to apoptosis. - **Carboplatin**: Forms DNA crosslinks, interfering with DNA replication and transcription in cancer cells, leading to cell death[2][3][5][7]. The combination is being evaluated in clinical trials based on preclinical synergy between TRK-950 and established chemotherapies[1][4].

Other names

caprin-1 antibody + gemcitabine + carboplatin